{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:39:49Z","timestamp":1790278789434,"version":"4.1.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","award":["no. 18CVD01"],"award-info":[{"award-number":["no. 18CVD01"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["no. 09120012010018"],"award-info":[{"award-number":["no. 09120012010018"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018890","name":"Dutch Cardiovascular Alliance","doi-asserted-by":"publisher","award":["no. 2020B005"],"award-info":[{"award-number":["no. 2020B005"]}],"id":[{"id":"10.13039\/100018890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020407","name":"European Research Area Network on Cardiovascular Diseases","doi-asserted-by":"publisher","award":["no. 2019T109"],"award-info":[{"award-number":["no. 2019T109"]}],"id":[{"id":"10.13039\/501100020407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR Biomedical Research Centre"],"award-info":[{"award-number":["NIHR Biomedical Research Centre"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Inherited cardiomyopathies caused by pathological genetic variants include multiple subtypes of heart disease. Advances in next-generation sequencing (NGS) techniques have allowed for the identification of numerous genetic variants as pathological variants. However, the disease penetrance varies among mutated genes. Some can be associated with more than one disease subtype, leading to a complex genotype-phenotype relationship in inherited cardiomyopathies. Previous studies have demonstrated disrupted metabolism in inherited cardiomyopathies and the importance of metabolic adaptations in disease onset and progression. In addition, genotype- and phenotype-specific metabolic alterations, especially in lipid metabolism, have been revealed. In this mini-review, we describe the metabolic changes that are associated with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), which account for the largest proportion of inherited cardiomyopathies. We also summarize the affected expression of genes involved in fatty acid oxidation (FAO) in DCM and HCM, highlighting the potential of PPARA-targeting drugs as FAO modulators in treating patients with inherited cardiomyopathies.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1114459","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T05:03:08Z","timestamp":1674104588000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting lipid metabolism as a new therapeutic strategy for inherited cardiomyopathies"],"prefix":"10.3389","volume":"10","author":[{"given":"Karen R.","family":"Gaar-Humphreys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wekking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"van Steenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Harakalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1253\/circj.CJ-14-0893","article-title":"Inherited cardiomyopathies.","volume":"78","author":"Towbin","year":"2014","journal-title":"Circ J."},{"key":"B2","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra0902923","article-title":"Inherited cardiomyopathies.","volume":"364","author":"Watkins","year":"2011","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41569-020-0428-2","article-title":"Epidemiology of the inherited cardiomyopathies.","volume":"18","author":"McKenna","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.116.309396","article-title":"Dilated cardiomyopathy: genetic determinants and mechanisms.","volume":"121","author":"McNally","year":"2017","journal-title":"Circ Res."},{"key":"B5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.053033","article-title":"Evidence-based assessment of genes in dilated cardiomyopathy.","volume":"144","author":"Jordan","year":"2021","journal-title":"Circulation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2025030118","DOI":"10.1073\/pnas.2025030118","article-title":"Hypertrophic cardiomyopathy \u03b2-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.","volume":"118","author":"Vander Roest","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.21542\/gcsp.2018.36","article-title":"The genetics of hypertrophic cardiomyopathy.","volume":"2018","author":"Akhtar","year":"2018","journal-title":"Glob Cardiol Sci Pract."},{"key":"B8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/CIRCRESAHA.113.300282","article-title":"Genetic cardiomyopathies causing heart failure.","volume":"113","author":"Cahill","year":"2013","journal-title":"Circ Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2020.12.290","article-title":"Clinical and biochemical footprints of inherited metabolic diseases. IV. Metabolic cardiovascular disease.","volume":"132","author":"Ferreira","year":"2021","journal-title":"Mol Genet Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"702920","DOI":"10.3389\/fcvm.2021.702920","article-title":"The role of metabolism in heart failure and regeneration.","volume":"8","author":"Bae","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0188-4409(03)00004-3","article-title":"Heart metabolic disturbances in cardiovascular diseases.","volume":"34","author":"Carvajal","year":"2003","journal-title":"Arch Med Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0735-1097(02)01967-8","article-title":"Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy.","volume":"40","author":"D\u00e1vila-Rom\u00e1n","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fcvm.2018.00068","article-title":"Loss of metabolic flexibility in the failing heart.","volume":"5","author":"Karwi","year":"2018","journal-title":"Front Cardiovasc Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/jcm9030694","article-title":"Inherited metabolic diseases and cardiac pathology in adults: diagnosis and prevalence in a CardioMetabo study.","volume":"9","author":"Brailova","year":"2020","journal-title":"J Clin Med Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/eurheartj\/ehx808","article-title":"Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias.","volume":"39","author":"Verdonschot","year":"2018","journal-title":"Eur Heart J."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.30.402792","article-title":"Transcriptional regulation profiling reveals disrupted lipid metabolism in failing hearts with a pathogenic phospholamban mutation.","author":"Pei","year":"2020","journal-title":"bioRxiv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e008532","DOI":"10.1161\/CIRCHEARTFAILURE.121.008532","article-title":"Protein aggregation is an early manifestation of phospholamban p.(Arg14del)\u2013related cardiomyopathy: development of PLN-R14del\u2013related cardiomyopathy.","volume":"14","author":"Eijgenraam","year":"2021","journal-title":"Circ Heart Fail."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e13074","DOI":"10.15252\/emmm.202013074","article-title":"Impairment of the ER\/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation.","volume":"13","author":"Cuello","year":"2021","journal-title":"EMBO Mol Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000524722","article-title":"Metabolic and metabolomics insights into dilated cardiomyopathy.","volume":"78","author":"Ampong","year":"2022","journal-title":"Ann Nutr Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3390\/ijms22041999","article-title":"Energy metabolites as biomarkers in ischemic and dilated cardiomyopathy.","volume":"22","author":"Haas","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B21","first-page":"817","article-title":"Integrated landscape of cardiac metabolism in end-stage human nonischemic dilated cardiomyopathy.","volume":"1","author":"Flam","year":"2022","journal-title":"Nat Cardiovasc Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cardfail.2019.09.004","article-title":"Metabolic profiling associates with disease severity in nonischemic dilated cardiomyopathy.","volume":"26","author":"Verdonschot","year":"2020","journal-title":"J Card Fail."},{"key":"B23","doi-asserted-by":"publisher","first-page":"597546","DOI":"10.3389\/fcvm.2020.597546","article-title":"Plasma metabolomic profiles differentiate patients with dilated cardiomyopathy and ischemic cardiomyopathy.","volume":"7","author":"Zhao","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"622236","DOI":"10.3389\/fcvm.2020.622236","article-title":"Characteristics of blood metabolic profile in coronary heart disease, dilated cardiomyopathy and valvular heart disease induced heart failure.","volume":"7","author":"Liu","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.cardfail.2013.10.010","article-title":"Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy.","volume":"19","author":"Bell","year":"2013","journal-title":"J Card Fail."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1210\/jc.2009-1293","article-title":"LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance.","volume":"95","author":"Boschmann","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11154-020-09568-3","article-title":"Clinical manifestations and management of fatty acid oxidation disorders.","volume":"21","author":"Merritt","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"key":"B28","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1093\/eurheartj\/ehac305","article-title":"Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy.","volume":"43","author":"Perea-Gil","year":"2022","journal-title":"Eur Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1016\/j.celrep.2018.03.017","article-title":"Serine availability influences mitochondrial dynamics and function through lipid metabolism.","volume":"22","author":"Gao","year":"2018","journal-title":"Cell Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/cvr\/cvy147","article-title":"Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.","volume":"114","author":"van der Velden","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B31","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1074\/jbc.RA118.001938","article-title":"Dilated cardiomyopathy myosin mutants have reduced force-generating capacity.","volume":"293","author":"Ujfalusi","year":"2018","journal-title":"J Biol Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1161\/CIRCRESAHA.107.156380","article-title":"Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments.","volume":"101","author":"Robinson","year":"2007","journal-title":"Circ Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/medicina58010031","article-title":"Oxidative stress markers in hypertrophic cardiomyopathy.","volume":"58","author":"Szygu\u0142a-Jurkiewicz","year":"2022","journal-title":"Medicina."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/s0735-1097(02)03009-7","article-title":"Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.","volume":"41","author":"Crilley","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/emmm.201302852","article-title":"Metabolic crosstalk between the heart and liver impacts familial hypertrophic cardiomyopathy.","volume":"6","author":"Magida","year":"2014","journal-title":"EMBO Mol Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.12997\/jla.2020.9.1.66","article-title":"CD36 (SR-B2) as a target to treat lipid overload-induced cardiac dysfunction.","volume":"9","author":"Glatz","year":"2020","journal-title":"J Lipid Atheroscler."},{"key":"B37","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1161\/CIRCULATIONAHA.121.053575","article-title":"Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy.","volume":"144","author":"Ranjbarvaziri","year":"2021","journal-title":"Circulation."},{"key":"B38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13148-021-01043-3","article-title":"Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations.","volume":"13","author":"Pei","year":"2021","journal-title":"Clin Epigenet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e007022","DOI":"10.1161\/CIRCHEARTFAILURE.120.007022","article-title":"Proteomic and functional studies reveal detyrosinated tubulin as treatment target in sarcomere mutation-induced hypertrophic cardiomyopathy.","volume":"14","author":"Schuldt","year":"2021","journal-title":"Circ Heart Fail."},{"key":"B40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1161\/CIRCRESAHA.119.315483","article-title":"Metabolic remodeling promotes cardiac hypertrophy by directing glucose to aspartate biosynthesis.","volume":"126","author":"Ritterhoff","year":"2020","journal-title":"Circ Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy.","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1172\/JCI1940","article-title":"Diastolic dysfunction and altered energetics in the alphaMHC403\/+ mouse model of familial hypertrophic cardiomyopathy.","volume":"101","author":"Spindler","year":"1998","journal-title":"J Clin Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12947-019-0171-1","article-title":"Genetic relevance and determinants of mitral leaflet size in hypertrophic cardiomyopathy.","volume":"17","author":"Chung","year":"2019","journal-title":"Cardiovasc Ultrasound."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation."},{"key":"B45","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1039\/c4mb00594e","article-title":"Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy.","volume":"11","author":"Gehmlich","year":"2015","journal-title":"Mol Biosyst."},{"key":"B46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1113\/JP275050","article-title":"Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament.","volume":"596","author":"Kampourakis","year":"2018","journal-title":"J Physiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet."},{"key":"B48","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jacc.2005.10.041","article-title":"Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation.","volume":"47","author":"Marian","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.108.790501","article-title":"Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms.","volume":"119","author":"Lombardi","year":"2009","journal-title":"Circulation."},{"key":"B50","doi-asserted-by":"publisher","first-page":"H1720","DOI":"10.1152\/ajpheart.00339.2015","article-title":"N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy.","volume":"309","author":"Wilder","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijcard.2019.12.002","article-title":"RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy.","volume":"302","author":"Hall","year":"2020","journal-title":"Int J Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/metabo11040195","article-title":"Metabolic signature of arrhythmogenic cardiomyopathy.","volume":"11","author":"Volani","year":"2021","journal-title":"Metabolites."},{"key":"B53","doi-asserted-by":"publisher","first-page":"103935","DOI":"10.1016\/j.isci.2022.103935","article-title":"Changes in transcriptomic landscape in human end-stage heart failure with distinct etiology.","volume":"25","author":"Zhu","year":"2022","journal-title":"iScience."},{"key":"B54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease.","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e012673","DOI":"10.1161\/JAHA.119.012673","article-title":"Glucose metabolism in cardiac hypertrophy and heart failure.","volume":"8","author":"Tran","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B56","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.molmet.2014.07.010","article-title":"Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling.","volume":"3","author":"Schugar","year":"2014","journal-title":"Mol Metab."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","article-title":"Implications of altered ketone metabolism and therapeutic ketosis in heart failure.","volume":"141","author":"Selvaraj","year":"2020","journal-title":"Circulation."},{"key":"B58","doi-asserted-by":"publisher","first-page":"9244","DOI":"10.1007\/s12410-013-9244-y","article-title":"Imaging of myocardial oxidative metabolism in heart failure.","volume":"7","author":"Naya","year":"2014","journal-title":"Curr Cardiovasc Imaging Rep."},{"key":"B59","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-019-0892-3","article-title":"Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure.","volume":"18","author":"Uddin","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"B60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/A:1006825028170","article-title":"Adenine nucleotide translocator in dilated cardiomyopathy: pathophysiological alterations in expression and function.","volume":"174","author":"D\u00f6rner","year":"1997","journal-title":"Mol Cell Biochem."},{"key":"B61","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/cvr\/cvr071","article-title":"Glucose metabolism and cardiac hypertrophy.","volume":"90","author":"Kolwicz","year":"2011","journal-title":"Cardiovasc Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.nuclcard.2006.12.329","article-title":"Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the \u03b1-tropomyosin gene: a positron emission tomography study.","volume":"14","author":"Tuunanen","year":"2007","journal-title":"J Nucl Cardiol."},{"key":"B63","doi-asserted-by":"crossref","first-page":"e009521","DOI":"10.1161\/CIRCHEARTFAILURE.121.009521","article-title":"Defects in the proteome and metabolome in human hypertrophic cardiomyopathy.","volume":"15","author":"Previs","year":"2022","journal-title":"Circ Heart Fail."},{"key":"B64","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF02001405","article-title":"Increased uracil nucleotide metabolism during the induction of cardiac hypertrophy by \u03b2-stimulation in rats.","volume":"75","author":"Rossi","year":"1980","journal-title":"Basic Res Cardiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11306-016-0956-2","article-title":"A targeted metabolomics assay for cardiac metabolism and demonstration using a mouse model of dilated cardiomyopathy.","volume":"12","author":"West","year":"2016","journal-title":"Metabolomics."},{"key":"B66","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-04817-8","article-title":"Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy.","volume":"608","author":"Chaffin","year":"2022","journal-title":"Nature."},{"key":"B67","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/biom12050731","article-title":"Transcriptomal insights of heart failure from normality to recovery.","volume":"12","author":"Quttainah","year":"2022","journal-title":"Biomolecules."},{"key":"B68","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1074\/jbc.M113.531384","article-title":"Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism.","volume":"289","author":"Prosdocimo","year":"2014","journal-title":"J Biol Chem."},{"key":"B69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s42485-019-00004-y","article-title":"Quantitative proteomics study reveals differential proteomic signature in dilated, restrictive, and hypertrophic cardiomyopathies.","volume":"10","author":"Ghose","year":"2019","journal-title":"J Proteins Proteomics."},{"key":"B70","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40256-022-00532-x","article-title":"The impact of mavacamten on the pathophysiology of hypertrophic cardiomyopathy: a narrative review.","volume":"22","author":"Edelberg","year":"2022","journal-title":"Am J Cardiovasc Drugs."},{"key":"B71","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/01.CIR.0000139340.88769.D5","article-title":"Cardiac metabolism as a target for the treatment of heart failure.","volume":"110","author":"Taegtmeyer","year":"2004","journal-title":"Circulation."},{"key":"B72","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.2147\/DDDT.S269514","article-title":"SGLT2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy.","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des Devel Ther."},{"key":"B73","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1093\/eurheartj\/ehaa530","article-title":"Regression of left ventricular hypertrophy with SGLT2 inhibitors.","volume":"41","author":"Paneni","year":"2020","journal-title":"Eur Heart J."},{"key":"B74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects.","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ejhf.2414","article-title":"Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC).","volume":"24","author":"de Boer","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B76","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.pathol.2021.06.119","article-title":"HADHB, a fatty acid beta-oxidation enzyme, is a potential prognostic predictor in malignant lymphoma.","volume":"54","author":"Sekine","year":"2022","journal-title":"Pathology."},{"key":"B77","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1194\/jlr.R005959","article-title":"Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism.","volume":"51","author":"Van Veldhoven","year":"2010","journal-title":"J Lipid Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.3390\/cells9112367","article-title":"The role of PPARs in disease.","volume":"9","author":"Wagner","year":"2020","journal-title":"Cells."},{"key":"B79","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bbalip.2007.02.013","article-title":"PPARs and molecular mechanisms of transrepression.","volume":"1771","author":"Ricote","year":"2007","journal-title":"Biochim Biophys Acta."},{"key":"B80","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions.","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat Rev Cardiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejheart.2005.09.003","article-title":"Cardiac PPAR\u03b1 expression in patients with dilated cardiomyopathy.","volume":"8","author":"Schupp","year":"2006","journal-title":"Eur J Heart Fail."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e86898","DOI":"10.1172\/jci.insight.86898","article-title":"Molecular profiling of dilated cardiomyopathy that progresses to heart failure.","volume":"1","author":"Burke","year":"2016","journal-title":"JCI Insight."},{"key":"B83","doi-asserted-by":"publisher","first-page":"201625","DOI":"10.1155\/2015\/201625","article-title":"KLF15 and PPAR\u03b1 cooperate to regulate cardiomyocyte lipid gene expression and oxidation.","volume":"2015","author":"Prosdocimo","year":"2015","journal-title":"PPAR Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms19113464","article-title":"Elucidating the beneficial role of PPAR agonists in cardiac diseases.","volume":"19","author":"Khuchua","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543776.2020.1703952","article-title":"Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).","volume":"30","author":"Takada","year":"2020","journal-title":"Expert Opin Ther Pat."},{"key":"B86","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications\u2013a review.","volume":"13","author":"Grygiel-G\u00f3rniak","year":"2014","journal-title":"Nutr J."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/ijms19082189","article-title":"The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development.","volume":"19","author":"Hong","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence.","volume":"20","author":"Cheng","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/liv.14165","article-title":"Additional fibrate treatment in UDCA-refractory PBC patients.","volume":"39","author":"Chung","year":"2019","journal-title":"Liver Int."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.jacc.2021.08.021","article-title":"Investigating lipid-modulating agents for prevention or treatment of COVID-19: JACC state-of-the-art review.","volume":"78","author":"Talasaz","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"154798","DOI":"10.1016\/j.metabol.2021.154798","article-title":"Fenofibrate, a PPAR\u03b1 agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy.","volume":"120","author":"Yoo","year":"2021","journal-title":"Metabolism."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.3390\/cells11203184","article-title":"Activation of PPAR\u03b1 ameliorates cardiac fibrosis in Dsg2-deficient arrhythmogenic cardiomyopathy.","volume":"11","author":"Qiu","year":"2022","journal-title":"Cells."},{"key":"B93","doi-asserted-by":"crossref","first-page":"e11589","DOI":"10.15252\/emmm.201911589","article-title":"Metabolic effects of bezafibrate in mitochondrial disease.","volume":"12","author":"Steele","year":"2020","journal-title":"EMBO Mol Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jocn.2018.10.046","article-title":"Neutral lipid storage disease with myopathy and dropped head syndrome. Report of a new variant susceptible of treatment with late diagnosis.","volume":"58","author":"Garcia","year":"2018","journal-title":"J Clin Neurosci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1212\/WNL.0000000000000118","article-title":"Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.","volume":"82","author":"\u00d8rngreen","year":"2014","journal-title":"Neurology."},{"key":"B96","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s10038-018-0527-7","article-title":"Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.","volume":"64","author":"Yamada","year":"2019","journal-title":"J Hum Genet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"100610","DOI":"10.1016\/j.ymgmr.2020.100610","article-title":"Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency.","volume":"24","author":"Suyama","year":"2020","journal-title":"Mol Genet Metab Rep."},{"key":"B98","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/clpt.2010.55","article-title":"Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency.","volume":"88","author":"Bonnefont","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jimd.12453","article-title":"Current and future treatment approaches for Barth syndrome.","volume":"45","author":"Thompson","year":"2022","journal-title":"J Inherit Metab Dis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1634\/stemcells.2007-0532","article-title":"Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism.","volume":"26","author":"Sharifpanah","year":"2008","journal-title":"Stem Cells."},{"key":"B101","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000492875","article-title":"Targeting peroxisome proliferator activated receptor \u03b1 (PPAR \u03b1) for the prevention of mitochondrial impairment and hypertrophy in cardiomyocytes.","volume":"49","author":"Kar","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B102","doi-asserted-by":"publisher","first-page":"5609121","DOI":"10.1155\/2016\/5609121","article-title":"Peroxisome proliferator-activated receptor \u03b1 reduces endothelin-1-caused cardiomyocyte hypertrophy by inhibiting nuclear factor- \u03ba B and adiponectin.","volume":"2016","author":"Jen","year":"2016","journal-title":"Mediators Inflamm."},{"key":"B103","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lfs.2015.01.015","article-title":"Effects of ERK1\/2\/PPAR\u03b1\/SCAD signal pathways on cardiomyocyte hypertrophy induced by insulin-like growth factor 1 and phenylephrine.","volume":"124","author":"Huang","year":"2015","journal-title":"Life Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/cells9020352","article-title":"PPAR-mediated toxicology and applied pharmacology.","volume":"9","author":"Xi","year":"2020","journal-title":"Cells."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1114459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T16:29:47Z","timestamp":1674664187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1114459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":104,"alternative-id":["10.3389\/fcvm.2023.1114459"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1114459","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"article-number":"1114459"}}